COYA.US Coya Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
3.13 USD
Close of Nov 13, 2026
2.72 6.62
Market cap
USD 73.4M
P/E
-
P/B
2.29x
ROE
-97.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is COYA.US undervalued?

Graham number

The Graham number of Coya Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Coya Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Coya Therapeutics, Inc. Common Stock yet.

Coya Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Coya Therapeutics, Inc. Common Stock

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector fu…

Full company profile